Advances in NSCLC Treatment – Overcoming Osimertinib Resistance and Exploring the Potential of Amivantamab and Lazertinib
In the ever-evolving landscape of cancer treatment, recent breakthroughs in the fight against non-small cell lung cancer (NSCLC) have brought new hope to patients and clinicians alike. At the forefront of these advancements is the remarkable progress in understanding and targeting mutations in the epidermal